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ABSTRACT
Introduction: Sub-Saharan African (SSA) women with
breast cancer (BC) have low survival rates from this
potentially treatable disease. An understanding of
context-specific societal, health-systems and woman-
level barriers to BC early detection, diagnosis and
treatment are needed.
Methods: The African Breast Cancer—Disparities in
Outcomes (ABC-DO) is a prospective hospital-based
study of overall survival, impact on quality of life (QOL)
and delays along the journey to diagnosis and treatment
of BC in SSA. ABC-DO is currently recruiting in Namibia,
Nigeria, South Africa, Uganda and Zambia. Women aged
18 years or older who present at participating secondary
and tertiary hospitals with a new clinical or
histocytological diagnosis of primary BC are invited to
participate. For consented women, tumour
characteristics, specimen and treatment data are
obtained. Over a 2-year enrolment period, we aim to
recruit 2000 women who, in the first instance, will be
followed for between 1 and 3 years. A face-to-face
baseline interview obtains information on
socioeconomic, cultural and demographic factors, QOL,
health and BC attitudes/knowledge, and timing of all
prediagnostic contacts with caregivers in orthodox
health, traditional and spiritual systems. Responses are
immediately captured on mobile devices that are fed into
a tailored mobile health (mHealth) study management
system. This system implements the study protocol, by
prompting study researchers to phone women on her
mobile phone every 3 months and, failing to reach her,
prompts contact with her next-of-kin. At follow-up calls,
women provide updated information on QOL, care
received and disease impacts on family and working life;
date of death is asked of her next-of-kin when relevant.
Ethics and dissemination: The study was approved
by ethics committees of all involved institutions. All
participants provide written informed consent. The
findings from the study will be published in peer-
reviewed scientific journals, presented to funders and
relevant local organisations and at scientific conferences.
BACKGROUND
Similar to global patterns, breast cancer is the
most common cancer in women in
sub-Saharan Africa (SSA),1 with 94 000 new
cases of breast cancer and 48 000 deaths due
to breast cancer occurring in 2012. This
burden is projected to double between 2012
and 2030 due to population ageing and expan-
sion.2 While breast cancer is, on average, a
good-prognosis cancer in high-income coun-
tries, in SSA its prognosis is considerably
lower.3 Excessive deaths due to breast cancer
are reﬂected in a high breast cancer mortality:
incidence ratio of 0.50 in SSA in 2012, twice
that of Western Europe (0.24).2
Research on survival and outcomes of
women having breast cancer in SSA is scarce.
Strengths and limitations of this study
▪ This protocol describes an ongoing prospective
cohort study across five countries in
sub-Saharan Africa (emphasising a
within-African cross-country perspective).
▪ The study uses a mHealth tool for study man-
agement and standardisation of data collection in
real-time.
▪ The generic set-up of the study’s mobile plat-
form means that other funded sites could easily
join African Breast Cancer—Disparities in
Outcomes (ABC-DO).
▪ The African settings pose many challenges—for
example, minimising losses to follow-up, and
obtaining valid information on disease progres-
sion and mortality.
▪ This is a hospital-based study and, hence, will
not capture the experience of women who solely
seek care elsewhere (eg, traditional or spiritual
healers).
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Among the studies that have been conducted, the 5-year
survival estimates of women having breast cancer reveal
that the 5-year survival estimates are near or below 50% in
SSA,4–8 contrasting with 73% and 85% among black and
white women in the US, respectively.9 However, many of
these SSA studies are now either outdated,4–7 were con-
ducted retrospectively,5 10 11 or with no linkable vital status
registers and active follow-up; their losses to follow-up were
often large adding uncertainty to survival estimates. In
addition, prognostic and predictive factors examined were
limited to only a few clinical and therapeutic factors.5 8 10–
12 Of these factors, improved survival was found for
women diagnosed at stages I/II than for those diagnosed
at stages III/IV,5 6 8 12 demonstrating the potential to save
lives if down staging could be achieved. Nevertheless, the
potential for survival gains may be hampered by the rela-
tively young patient proﬁle in SSA, reﬂecting the young
age structure of the underlying population, as younger age
is associated with poorer survival.13 Further, while a pre-
dominance of more aggressive breast cancer subtypes (eg,
triple-negative tumours) in some settings would impede
survival prospects,14 15 the totality of evidence across SSA
from the largest studies and from a meta-analysis demon-
strate a clear predominance of better prognosis oestrogen
receptor-positive tumours.16 17
An updated prospective and more comprehensive
study of the entire journey of women with breast
cancer in SSA is needed, that is, the journey from her
ﬁrst noticing symptoms through to the postdiagnostic
treatment period and to subsequent disease cure,
recurrence or spread. Inﬂuences on certain compo-
nents of this journey have previously been studied in
the SSA setting. Treatment received may depend on
its availability, affordability, accessibility, quality and
adherence in the presence of other comorbidities,
and also its acceptability to patients who use trad-
itional or other healers for healthcare.18 Patients may
not complete the recommended treatment courses,
due to lack of funds, no bed space in the hospital
and particular to some settings, feeling well after
initial treatment—the ‘paradox of wellness and non-
adherence’.19–21 Further, for the multidisciplinary
management of breast cancer, not all SSA health
systems have accessible and adequate diagnostic and
treatment facilities.22 Radiotherapy facilities in par-
ticular are lacking in much of SSA, while centralised
oncology facilities are often at large distances from
rural health centres and women’s homes. Finally, SSA
settings have a considerable number of HIV-positive
patients with breast cancer23 whose survival and treat-
ment tolerance need further investigation.24
On the basis of the available literature and the research
teams’ experience in SSA, we hypothesised that:
▸ Poor survival from breast cancer in Africa is largely
attributed to, in descending order of magnitude: late
stage at diagnosis, lack of access to and compliance with
appropriate treatment, tumour aggressiveness and
comorbidities.
▸ Breast cancer survival probabilities in certain African
settings are better than in others, demonstrating real-
istic improvements that can be achieved to avoid
deaths from this disease.
▸ Lack of receptor status testing impacts on survival of
women suffering from breast cancer especially for
early stage disease.
▸ Inappropriate treatment and lack of treatment adher-
ence, due to poor availability of treatment, its lack of
affordability and toxicity (eg, due to coexisting HIV),
contribute to poor survival of women suffering from
breast cancer.
▸ A woman’s socioeconomic position, education and
culture inﬂuence her health beliefs and health
seeking behaviour both prior to and post breast
cancer diagnosis.
The African Breast Cancer—Disparities in Outcomes
(ABC-DO) study was designed speciﬁcally to examine
the entire breast cancer journey and test these
hypotheses.
METHODS AND ANALYSIS
Study design overview
ABC-DO is a hospital-based prospective observational
study of outcomes after breast cancer diagnosis in ﬁve SSA
countries: Namibia and South Africa in Southern Africa,
Zambia and Uganda in eastern Africa and Nigeria in
western Africa. Recruitment initiation was staggered across
the participating hospitals, between September 2014 and
early 2016 (table 1). At each site, over a 2-year period of
enrolment, all women newly diagnosed with breast cancer
are invited to participate in the study. Participation involves
a baseline face-to-face interview with a study research assist-
ant (RA) on the woman’s presentation at the participating
hospital, after which each participant is followed up by
mobile phone for, in the ﬁrst instance, at least one and up
to 3 years (ie, with the funding presently in place). Data
on factors hypothesised to have a direct impact on survival
(proximal factors) such as tumour biology and treatment
received are predominantly extracted from hospital
records (patient notes, pathology reports, etc), using a
standardised study proforma. Factors hypothesised to have
an indirect impact on survival (distal factors) such as socio-
economic factors that inﬂuence diagnosis delays (ﬁgure 1)
are obtained directly from the participants during the
baseline interview. The full prediagnostic experience from
ﬁrst symptom recognition, every contact with caregivers,
through to diagnosis are also obtained at baseline inter-
view (ﬁgure 2).
At three-monthly intervals after the baseline interview,
the study RA telephones the woman, or when appropri-
ate, her next-of-kin, to obtain data on vital status, treat-
ment side effects, treatment compliance and health
status and possible barriers to healthcare utilisation and
treatment adherence. To implement this protocol and
to reduce losses to follow-up, mHealth technologies are
used throughout.
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Table 1 Characteristics of ABC-DO participating hospital, their catchment populations and expected patient with breast cancer profile
Country (ordered by date
recruitment started) Namibia Nigeria Uganda South Africa Zambia
National estimates of age-standardised breast cancer rates, per 100 000 women*
Incidence 24.4 50.4 27.5 41.5 22.4
Mortality 9.6 25.9 13.6 16.5 11.1
National adult HIV
prevalence in adults aged
15–49 years, 2011–2015†
16.0% 3.2% 7.3% 19% 12.4%
ABC-DO recruitment
hospital
Windhoek Central
Hospital, Windhoek
(capital)
1. ABSUTH, Aba,
Abia State
2. Owerri Federal
Medical Centre,
Owerri, Imo
State
Mulago Hospital Complex in
Kampala (capital), including:
1. Uganda Cancer Institute
2. Mulago Hospital
Chris Hani
Baragwanath Hospital,
Soweto, Gauteng
1. UTH, Lusaka
2. CDH, Lusaka
3. KGH, Kabwe, Central
province
Initiation of recruitment September 2014 November 2014 December 2014 August 2015‡ April 2016
Type of hospital National tertiary
referral
Federal secondary
hospital
National tertiary referral Tertiary referral UTH: national tertiary; CDH:
cancer-specialised tertiary;
KGH: provincial hospital
Source population of
hospital(s) (both sexes, all
ages)
Entire population (2.4
million) of Namibia,
residing up to 800 km
away
Abia State: 3
million,
Imo State: 4 million
National public referral hospital,
serving the entire population
(35.6 million) of Uganda, residing
up to 500 km away
Population of Soweto
(2 million) mostly
residing within 50 km
For UTH and CDH: entire
population (13.9 million) of
Zambia, residing up to 800 km
away
Majority ethnic groups of
patients
Various, including
white, Ovambo,
Damara.
Igbo Bantu—Ganda, Nkole 90% black Xhosa,
Sotho, Zulu
Bantu—Bemba, Tonga
Expected annual number
of newly diagnosed
women with breast
cancers
250 150 250 300 150
Mean or median age at
diagnosis§
53 43 45 55 49¶
Referral routes Nationwide referrals
from public and private
sectors
Nationwide
referrals from
public and private
sectors
Primary hospital referrals and
self-referral
Referred from local
hospital
Referred from local hospitals
and outreach clinics
Stage at diagnosis (%)§
I, II, III, IV
5, 14, 71, 10 10, 20, 50, 20 5, 15, 40, 40 7, 45, 40, 8 10¶, 36¶, 54¶
Availability of diagnostic and treatment facilities
Mammography–
ultrasound
Yes–Yes Yes–Yes Yes–Yes Yes–Yes Yes–Yes
Cytology–histology Yes–Yes Yes–Yes Yes–Yes Yes–Yes Yes–Yes
Surgery–chemotherapy–
radiotherapy
Yes–Yes–Yes Yes–Yes–Not
locallys**
Yes–Yes–Yes Yes–Yes–Yes Yes–Yes–Yes
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Study settings
Hospitals participating in ABC-DO to date are settings
where: International Agency for Research on Cancer
(IARC) had already established,16–25 or were developing,
a successful collaboration in breast cancer research; the
site has at least 100 newly diagnosed women with breast
cancer each year; and the selected sites together span
countries and hospitals with contrasting patient proﬁles,
catchment populations and health systems. Notably,
ABC-DO countries are at different stages of the breast
cancer transition, with breast cancer age-standardised
incidence rates per 100 000 women in 2012 ranging
from 22–28 in Zambia, Namibia and Uganda, to 42–50
in South Africa and Nigeria.2 The key characteristics of
each site are summarised in table 1. All settings are
located in the largest metropolitan area of the respective
country, with the exception of the Nigerian hospitals,
which are based in neighbouring south-eastern states of
Abia and Imo. The Namibian and South African settings
are similar in terms of routine at-diagnosis
triple-receptor assessment, affordable care to most resi-
dent patients, and availability of surgery, chemotherapy,
radiotherapy and hormonal therapy. Both settings also
have a relatively high HIV prevalence among the
general population, and thus among younger patients
with breast cancer.23 However, these two sites have con-
trasting catchment populations; Windhoek Central
Hospital serves the entire country of Namibia while the
Chris Hani Baragwanath Academic Hospital serves a
similarly sized local population within a 50 km radius of
Soweto. Treatment expenses also vary by setting, with a
range of minimal fees, which are often waived, to fees
fully paid for by the patient and/or their families. In the
Nigerian, Ugandan and Zambian sites, access to stand-
ard diagnostic and therapeutic management depends
greatly on its availability at the time of treatment, as well
as affordability to patients.
Participant inclusion/exclusion
Women eligible for inclusion in ABC-DO are those who
have conﬁrmed primary breast cancer, through either a
histopathological/cytological or clinical diagnosis, are
aged 18 years or over at the time of diagnosis and are
being newly seen at the participating hospital. All such
patients are invited to participate regardless of their
stage at diagnosis, ethnicity/race, country of origin, or
place of current or past residence, previous history of no
breast cancer or of any treatment considerations (treat-
ment type, intention, affordability, private/public
sector). A patient who had preliminary surgery or con-
ﬁrmatory biopsy at another clinic and subsequently
referred to the participating ABC-DO hospital for
further treatment is eligible. Patients who present with a
second primary breast cancer are also eligible. There is
the potential that some enrolled women will in fact
present with recurrences rather than a second primary
cancer—full diagnostic and treatment details of any pre-
vious breast problem, including breast cancer, are being
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obtained from all women so that at a later stage, all
women reporting a positive history can be evaluated and
excluded where appropriate. A patient who has already
started her treatment for breast cancer at a participating
hospital is not eligible.
Where tissue/cell sampling is performed, on histo
(cyto)pathological conﬁrmation, women diagnosed with
either in-situ (International Classiﬁcation of Diseases,
10th Revision (ICD-10) D05) or invasive breast carcin-
omas (ICD-10 C50) remain included, whereas if
microscopic evaluation indicates a benign lesion (eg,
ICD-10 D24), the patient is excluded. If histo(cyto)
pathological evaluation is not performed or the micro-
scopic diagnosis, for any reason, remains indeterminable
but her physician is treating her for breast cancer, the
woman remains in the study. Clinically diagnosed breast
cancers are included, because ABC-DO is an observa-
tional study, which attempts to capture the reality of the
breast cancer situation in each setting; the study itself
does not fund, and thus does not require, histo(cyto)
Figure 1 Pathways under investigation for overall survival after breast cancer diagnosis, and for intermediate landmarks on a
women’s journey with breast cancer. QOL, quality of life.
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pathological conﬁrmation for enrolment, but if tissue is
taken as part of the routine diagnostic work-up, consent
to use it for research is obtained.
Enrolment and baseline interview
All women presenting with suspected breast cancer diag-
nosis are invited to participate in ABC-DO; we do not wait
until the diagnosis is conﬁrmed to start identiﬁcation of
cases as some women never return for diagnosis and
treatment. Through close liaison between clinicians and
study RAs, the latter are alerted whenever the clinician
identiﬁes a suspected new patient with breast cancer.
Before the treatment begins, the RA approaches the
woman. After providing study information, the woman
can choose to participate at that time, delay her decision
or not participate. The number of women who refuse
and their reason for refusal are being recorded, as is the
number of women who are too ill to participate.
If women consent to participate in the study, at a
minimum they are asked to complete the baseline inter-
view, provide access to their medical records and be fol-
lowed up through telephonic contact thereafter. The
baseline interview obtains information on breast cancer
risk factors, socioeconomic information, health attitudes,
knowledge and beliefs. Women are asked about the
dates they ﬁrst noticed their symptoms, and all further
dates when they informed another person or made
contact with any service, system or professional for help/
treatment/relief, including public and private health
facilities, traditional healers, faith healers and religious
institutions. The woman’s own knowledge of breast
cancer symptoms and causes are ascertained. At enrol-
ment women are given a study contact card with the
RA’s telephone number.
Clinical, pathological and treatment information
Standard proformas are used to record all clinical,
pathological and treatment information, or, to extract
these from medical notes, as per the local site’s prefer-
ence. During the diagnostic period, this information
includes clinical presentation of the breast mass, its size
and extension, and where available, histo(cyto)patho-
logical diagnosis and the status of receptors (oestrogen,
progesterone and HER2 via immunohistochemistry
(IHC) or ﬂuorescent in-situ hybridisation (FISH)). If
any of this information is not available, we also record
the reason why (eg, no capacity to perform test, patient
cannot pay for test, results indeterminable). The study
Figure 2 (A) Conceptual model of the time-line of the entire journey of a woman with breast cancer. (B) Information sourced
from the woman or her next-of-kin in African Breast Cancer—Disparities in Outcomes (ABC-DO). (C) Study information sourced
from hospital records.
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enrolment date is the date of baseline interview.
Thereafter, there may be signiﬁcant delays during the
diagnostic period, thus so as to not exclude this import-
ant time window where survival gains could be made,
the study RA obtains each of the dates at ﬁrst presenta-
tion, date of biopsy/cytology and date of histocytological
conﬁrmation. Patient management information is also
ascertained, including on surgical procedures, chemo-
therapy, hormonal therapy and palliative care. For each
treatment, the intended course is documented as well as
the actual received treatment, and where these deviate,
the reasons why. Updated disease status, including recur-
rence and metastases, will be recorded if and when the
woman returns to the hospital.
Biospecimen
At enrolment, women are also asked to provide consent
for their tumour specimen to be used for research pur-
poses (if such a specimen exists), including for genomic
studies and, if not already performed as part of the diag-
nostic work-up, for IHC. The type and timing of the
tumour specimen collection in relation to chemotherapy
initiation is individually recorded for each specimen.
Formalin-ﬁxed parafﬁn embedded tumour blocks will be
sent to IARC for histopathological review and comple-
mentary studies. At the end of the study, morphological
types, receptors’ status and molecular subtypes will be
independently evaluated at IARC and compared across
sites. In some sites, women are also asked to provide a
saliva sample for DNA extraction (Oragene DNA
research kits). The convenient room-temperature
storage of such samples makes them a viable solution for
standardised DNA collection.
Patient and next-of-kin contact: follow-up methodology
Most SSA countries have no national identiﬁcation
systems or linkable electronic records of vital status thus
ABC-DO requires a proactive approach to follow-up.
Every 3 months, women are contacted to repeatedly
update contact details for their next-of-kin. This tele-
phone call is also used to obtain information on health,
side-effects during treatments (neuropathy, hair loss),
indications of potential recurrence (pain in chest,
breathlessness, pain in armpit), care she is receiving and
any changes to her family and work life. If the woman
cannot be contacted repeatedly, the mHealth system
prompts the RA to telephone her next-of-kin; if they
inform the RA that the woman has passed away, informa-
tion on the date of death and cause of death are
obtained. In the instance where a death is reported by
the woman’s next-of-kin, while vital status and date of
death may be accurate, cause of death information will
be limited especially for patients who have multiple
chronic morbidities.
Maintaining contact with patients by mobile phone is
a novel methodological component, and, over the short-
term has been successful in Africa,26 but the present
study will evaluate the performance of this method over
longer periods of time. Contact rates may be compro-
mised by frequent changes of SIM cards or problems
with mobile phone network connectivity.
ABC-DO mHealth application
To facilitate data collection and assist in the complex study
management of timely contact with woman and/or their
next-of kin, a specialised mHealth study tool is being
employed. This application was speciﬁcally designed for
the purpose of the ABC-DO study by Mobenzi
Technologies (Pty), a South African mHealth solutions
company specialised in m-application (app) development
and support for health research. This m-technology has
been successfully implemented in several studies.27 28
Screen shots of the app are shown in ﬁgure 3. Some of its
features are:
▸ The app’s mobile interface is simple to use. Each RA
has a mobile phone (or tablet with call capability) for
data capture at the face-to-face baseline interview. At
follow-up interviews, the RA’s phone is used with a
headset to call the patient’s mobile or ﬁxed line, with
the RA immediately entering the woman’s responses
given over the telephone onto the app. All question-
naires/forms for each stage of data capture are con-
tained on the app and administered through the app.
Regardless of the complexity of the questionnaire,
RAs simply respond to each question one-by-one.
Automatic validation checks are incorporated, for
example, to check patient eligibility, and most ques-
tions are in the format of predeﬁned single or mul-
tiple options. There are few free-text ﬁelds and
standardised data are captured in easily analysable
formats.
▸ The ABC-DO app is installed on the RAs’ mobiles
and automatically communicates with the Mobenzi
web platform. Network connectivity is not required at
the time of data capture, but is needed to automatic-
ally upload captured data, after which no data remain
on the mobile phone.
▸ The web platform provides automatic coordination
and remote monitoring of the ﬁeldwork. Each RA’s
mobile phone downloads a ‘to do’ list daily with rele-
vant information on which patients are due follow-up.
Investigators are able to remotely track the progress
of the ﬁeldwork in real-time and keep in touch with
the RAs on the ground, creating a closer motivated
team.
▸ Data are encrypted and securely stored with access
control codes deﬁning levels of access (eg, local inves-
tigators have access to the data from their centre;
while the study coordinator has access to all the
data).
The above app is being used with one exception, the
South African site. Their breast clinic already had a suc-
cessfully operational database which contains informa-
tion for the clinical management of patients, and
treatment, as well as questions on barriers to diagnosis.
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Fields for the follow-up have been added so as to imple-
ment the ABC-DO design.
Data analysis plan
Overall survival analysis will be carried out using time
since ﬁrst presentation at the hospital as the relevant
timescale. Absolute survival probabilities overall, and
stratiﬁed by baseline characteristics, will be examined
using Kaplan-Meier curves for sites and subsets of
women of interest for example, by stage and for invasive
breast carcinoma only. Relative survival estimates29 will
be used to compare overall survival between sites as
background mortality rates differ greatly between coun-
tries, especially in HIV-endemic populations.
To investigate determinants of survival within sites,
Cox proportional hazard models will be used to estimate
relative risks of survival time since baseline interview
associated with explanatory variables including baseline
factors (eg, age, ethnicity, tumour characteristics) as well
as time-changing explanatory variables (eg, having
received chemotherapy, number of chemotherapy
rounds). Effects will be compared across sites before
pooling the data across sites and estimating effects in a
single Cox model stratiﬁed by site to account for
between-site differences in the baseline hazards of
Figure 3 (A) African Breast Cancer—Disparities in Outcomes (ABC-DO) mobile phone application: appearance of outer folder.
(B) A reminder to the research assistant to assign a new participating woman a new ID number. (C) Scanning of two-dimensional
ID barcodes avoids data entry errors. (D) Reports for treatment information. (E) Example of data entry screen for a numeric
response (age). (F) A constantly updated list of follow-up calls that are due (the names shown here do not correspond to the real
names of any of the study participants).
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death. In doing this, power will be gained to examine
less-common exposures (eg, the effect of non-adherence
to treatment, or survival in less common stages). To
investigate the indirect determinants of survival (eg,
socioeconomic factors, distance to hospital), crude HRs
will be compared with those adjusted for relevant clin-
ical variables to identify confounding and/or the path-
ways through which these indirect factors operate. We
will also investigate the duration of the prediagnostic
journey and its determinants using linear regression
models and logistic regression models for a diagnostic
journey of over 6 months, and for late-stage diagnosis.
Sample size
The study aims to evaluate proximal and distal determi-
nants of overall survival after breast cancer diagnosis, and
to do so separately in each participating country. In each
country, over 2 years of recruitment, smaller and larger
centres are expected to have, respectively, ∼300 and 500
women recruited, with an average 2-year follow-up time. As
diagnostic stage is a major prognostic factor, assuming
2-year survival probabilities of 0.85 for stage I/II and 0.5 for
stage III/IV, the number of deaths at a site with 50% stage
I/II disease is 100 and 160 for the smaller and larger sites,
respectively. With 100 deaths, for an exposure prevalence of
30% and 50%, the study will have 80% power to detect HRs
of 1.7 and 2.6; and in larger sites with 160 deaths, we have
the power to detect HRs of at least 1.5 and 2.1, respectively.
Potential for expansion
The generic set-up of the ABC-DO mHealth study plat-
form via an easily translatable and transportable
m-platform means that other funded sites, especially in
unrepresented francophone or lusophone Africa, are
welcome to join this initiative.
ETHICS AND DISSEMINATION
ABC-DO does not involve invasive procedures or the
alteration of standard clinical care. Patient information
sheets are available in local languages, and explain in lay
language the aims of the study, what the study involves
and what will be asked from the participants. To avoid
women agreeing to participate under false impressions
of beneﬁts to their treatment, the information sheets
emphasise that a woman’s participation: (1) will be
entirely voluntary and that the woman will be entitled to
withdraw at any time; (2) will not alter the standard clin-
ical care that she will be offered and (3) will not cover
diagnostic or treatment costs. Informed written consent
is obtained from literate women. Local/institutional
ethics guidelines are followed for obtaining proper
consent from illiterate women (eg, patient’s ﬁngerprint
as an alternative to a signature).
Findings from the study will be disseminated through
presentations at both international and African-focused
health conferences (eg, African Organisation for
Research and Training in Cancer), and submitted for
publication to international peer-reviewed journals.
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